Literature DB >> 16262747

Post-surgical assessment of excised tissue from patients with Buruli ulcer disease: progression of infection in macroscopically healthy tissue.

G Bretzel1, V Siegmund, P Racz, F van Vloten, F Ngos, W Thompson, P Biason, O Adjei, B Fleischer, J Nitschke.   

Abstract

OBJECTIVE: The current standard of treatment of Buruli ulcer disease (BUD) is surgical excision of lesions. Excision size is determined macroscopically assuming the complete removal of all infected tissue. However, dissemination of infection beyond the excision margins into apparently healthy tissue, possibly associated with recurrences, cannot be excluded in this way. To assess the central to peripheral progression of Mycobacterium ulcerans infection and the mycobacterial infiltration of excision margins, excised tissue was examined for signs of infection.
METHODS: 20 BUD lesions were excised in general anaesthesia including all necrotic and subcutaneous adipose tissue down to the fascia and at an average of 40 mm into the macroscopically unaffected tissue beyond the border of the lesion. Tissue samples were subjected to PCR and histopathology.
RESULTS: Although the bacillary load decreased from central to peripheral, M. ulcerans infection was detected throughout all examined tissue specimens including the peripheral segments as well as excision margins of all patients. During the post-operative hospitalization period (averaging 2 months) no local recurrences were observed.
CONCLUSION: Available data suggest a correlation of surgical techniques with local recurrences. The results of this study indicate the unnoticed early progression of mycobacterial infection into macroscopically healthy tissue. Thus, the removal of all infected tissue cannot always be verified visually by the surgeon. Provided that long-term follow up of patients with positive excision margins will establish the clinical relevance of these findings, on-site laboratory assessment of excised tissue in combination with follow up may contribute to reduce recurrence rates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16262747     DOI: 10.1111/j.1365-3156.2005.01507.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  5 in total

1.  What does detection of Mycobacterium ulcerans DNA in the margin of an excised Buruli ulcer lesion tell us?

Authors:  Simona Rondini; Ernestina Mensah-Quainoo; Thomas Junghanss; Gerd Pluschke
Journal:  J Clin Microbiol       Date:  2006-08-23       Impact factor: 5.948

2.  Excision of pre-ulcerative forms of Buruli ulcer disease: a curative treatment?

Authors:  K-H Herbinger; D Brieske; J Nitschke; V Siegmund; W Thompson; E Klutse; N Y Awua-Boateng; E Bruhl; L Kunaa; M Schunk; O Adjei; T Löscher; G Bretzel
Journal:  Infection       Date:  2008-12-03       Impact factor: 3.553

Review 3.  Pharmacologic management of Mycobacterium ulcerans infection.

Authors:  Tjip S Van Der Werf; Yves T Barogui; Paul J Converse; Richard O Phillips; Ymkje Stienstra
Journal:  Expert Rev Clin Pharmacol       Date:  2020-04-20       Impact factor: 4.108

4.  Genotyping Tools for Mycobacterium ulcerans-Drawbacks and Future Prospects.

Authors:  Charles A Narh; Lydia Mosi; Charles Quaye; Samuel Ck Tay; Bassirou Bonfoh; Dziedzom K de Souza
Journal:  Mycobact Dis       Date:  2014-05-05

5.  Detection of viable Mycobacterium ulcerans in clinical samples by a novel combined 16S rRNA reverse transcriptase/IS2404 real-time qPCR assay.

Authors:  Marcus Beissner; Dominik Symank; Richard Odame Phillips; Yaw Ampem Amoako; Nana-Yaa Awua-Boateng; Fred Stephen Sarfo; Moritz Jansson; Kristina Lydia Huber; Karl-Heinz Herbinger; Florian Battke; Thomas Löscher; Ohene Adjei; Gisela Bretzel
Journal:  PLoS Negl Trop Dis       Date:  2012-08-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.